Kolon TissueGene, Inc.

Languages

  • English
  • Korean
  • English
  • About
    • Overview
    • History
    • Management Team
    • Board of Directors
    • Advisory Boards
  • Technology
    • Overview
    • TG-C
    • Publications
  • Product Pipeline
    • Overview
    • Applications
  • Clinical Trials
  • IR
    • Stock Data
    • PR
    • IR Material
    • Disclosure
    • Analyst Report
  • Partnering/Alliances
  • Contact

PR

IR

IR

  • Stock Data
  • PR
  • IR Material
  • Disclosure
  • Analyst Report

Regenerative Medicine Company, TissueGene, adds Dr. Gurdyal Kalsi as Chief Medical Officer

Feb 16, 2016

TissueGene, Inc. Announces FDA Acceptance Of Invossa™ As Proprietary Name For TissueGene-C

Jun 24, 2015

TissueGene Announces Presentation and Webcast at the Jefferies 2015 Healthcare Conference

May 28, 2015

TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement with the Food and Drug Administration (FDA) for its Phase 3 Clinical Trial of Invossa™ for Patients Suffering from Osteoarthritis of the Knee

May 15, 2015

TissueGene, Inc. Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee

May 11, 2015

TissueGene, Inc. Hires Robert Newman as Chief Operating Officer

Apr 21, 2015

TissueGene Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of Osteoarthritis of the Knee

Nov 17, 2014

TissueGene Completes Enrollment in U.S. Phase II Study of TG-C in Patients with Knee Osteoarthritis

Nov 14, 2012

TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee

May 19, 2011
    • 1
    • 2
    © 2023 Kolon TissueGene, Inc. All Rights Reserved.

    This information—including product information—is intended only for residents of the United States. The products discussed on this site may have different labeling in different countries.

    Privacy Policy Disclaimer Sitemap Ethical Management